SCHEMBL7754750

SCHEMBL7754750

CC(C(=O)c1ccccc1)S(=O)(=O)C(C)C(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.48
ADRA2A P08913 1/20 0.48
ADRA2B P18089 1/20 0.48
HTR2A P28223 1/20 0.48
HRH1 P35367 1/20 0.48
KCNH2 Q12809 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
LMNA P02545 6/20 0.47
CES2 O00748 4/20 0.47
CES1 P23141 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
MAPT P10636 2/20 0.44
ATM Q13315 2/20 0.44
MDM2 Q00987 1/20 0.44
XBP1 P17861 1/20 0.44
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 4/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20867846 0.94 PGR (0.47) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL29012544 0.85 PGR (0.47) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL9772356 0.82 CA12 (0.49) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL10424358 0.82 TSSK1B (0.46) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL22189176 0.80 PGR (0.43) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL20867947 0.80 CES1 (0.44) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL5907933 0.80 PGR (0.47) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL9405228 0.79 PGR (0.42) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL13039632 0.77 LMNA (0.56) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL1397470 0.77 KMT2A (0.58) PGRADRA2AADRA2BHTR2AHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260077385-A1 FILM FORMING METHOD, CURABLE COMPOSITION, AND ARTICLE MANUFACTURING METHOD CANON KABUSHIKI KAISHA (JP) 2026-03-19 US disclosed
US-20260042932-A1 COMPOSITION, PATTERN FORMING METHOD, AND ARTICLE MANUFACTURING METHOD CANON KK (JP) 2026-02-12 US disclosed
EP-0634696-B2 Chemically amplified resist composition JAPAN SYNTHETIC RUBBER CO LTD (JP) 2001-01-31 EP disclosed
US-6114086-A COMPRISING ALKALI-SOLUBLE RESIN, DISSOLUTION CONTROLLING AGENTS, PHOTOACID GENERATOR, SOLVENT; USED FOR THE MANUFACTURE OF SEMICONDUCTOR DEVICES OR INTEGRATED CIRCUITS JSR CORPORATION (JP) 2000-09-05 US disclosed
US-5916729-A A POSITIVE TONE TYPE REISTS CONSISTS OF A RESIN WHICH HAS AN ACIDIC FUNCTIONAL GROUP PROTECTED BY AN ACID DECOMPOSABLE GROUP AND IS HYDROLYZABLE, A PHOTOACID GENERATOR AND A SOLVENT MIXTURE OF ALKYL LACTATE WITH PROPYLENE GLYCOL ETHER JSR CORPORATION (JP) 1999-06-29 US disclosed
EP-0634696-B1 Chemically amplified resist composition JAPAN SYNTHETIC RUBBER CO LTD (JP) 1998-01-14 EP disclosed
US-5629135-A ALKALI-SOLUBLE RESIN, CROSSLINKER, PHOTOACID GENERATOR, SOLVENT JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1997-05-13 US disclosed
EP-0634696-A1 Chemically amplified resist composition JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1995-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077385-A1 FILM FORMING METHOD, CURABLE COMPOSITION, AND ARTICLE MANUFACTURING METHOD EEF1D, RHOA, YWHAH PGR 3052/4885ADRA2A 3359/4885ADRA2B 3748/4885
US-20260042932-A1 COMPOSITION, PATTERN FORMING METHOD, AND ARTICLE MANUFACTURING METHOD SMCHD1, PIM1, PIM2 PGR 1493/4885ADRA2A 4447/4885ADRA2B 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.